The beneficial effects of vitamin D3 on reducing antibody titers against Epstein–Barr virus in multiple sclerosis patients

Najafipoor, Adeleh; Roghanian, Rasoul; Zarkesh-Esfahani, Hamid; Bouzari, Majid; Etemadifar, Masoud

doi:10.1016/j.cellimm.2015.01.009

Cited by 29 publications

(26 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with this, a recent study reported an initial decrease and a subsequent increase in serum concentrations of several pro-inflammatory cytokines in healthy individuals during repeated highdose oral vitamin D 3 supplementation. 31 In contrast to Najafipoor et al 28 who reported an effect of vitamin D 3 supplementation on antibody levels against both EBNA1 and VCA, we found a selective reduction in anti-EBNA1 IgG. 28 This discrepancy could be due to methodological factors, as different assays were used for anti-VCA IgG detection and the patients' disease duration and use of immunomodulatory treatment differed substantially between the studies.…”

Section: Discussioncontrasting

confidence: 95%

“…26 Accordingly, two subsequent open-label studies of vitamin D 3 supplementation in RRMS, which raised the mean and median levels of 25(OH)D to 113.4 and 380 nmol/L, respectively, reported an inverse correlation between anti-EBNA1 antibody and 25(OH)D concentrations. 27,28 In line with these studies, which had a follow-up between 12 and 24 weeks, we found that vitamin D 3 supplementation reduced antibody levels against EBNA1 after 48 weeks. However, this effect was no longer significant after 96 weeks.…”

Section: Discussionsupporting

confidence: 83%

See 1 more Smart Citation

Effect of high-dose vitamin D₃ supplementation on antibody responses against Epstein–Barr virus in relapsing-remitting multiple sclerosis

et al. 2016

View full text Add to dashboard Cite

Emerging evidence points to a viral infection, low levels of vitamin D and genetics as culprits in multiple sclerosis, but how they combine to cause the disease is unclear. TONY FOUHSE BY C A R O LY N B R O W N © 2 0 1 6 M a c m i l l a n P u b l i s h e r s L i m i t e d , p a r t o f S p r i n g e r N a t u r e. A l l r i g h t s r e s e r v e d. " The genetic contribution doesn't explain even half the risk. " OUTLOOK S 6 | N A T U R E | V O L 5 4 0 | 1 D E C E M B E R 2 0 1 6 MULTIPLE SCLEROSIS

show abstract

Section: Discussioncontrasting

confidence: 95%

Section: Discussionsupporting

confidence: 83%

Effect of high-dose vitamin D₃ supplementation on antibody responses against Epstein–Barr virus in relapsing-remitting multiple sclerosis

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The authors evaluated the clinical effectiveness of vitamin D supplementation in four systematic reviews (27–30), eight randomized controlled trials (24, 31–37), and three non-randomized studies (25, 38, 39). The authors of the CADTH Rapid Report concluded that “the outcomes of vitamin D supplementation for MS were heterogeneous, conflicting and inconsistent, with no effect on disability scores and relapse rates.…”

Section: Why Establish Phocis While a Trial Of Oral Vitamin D Supplemmentioning

confidence: 99%

Narrowband UVB Phototherapy for Clinically Isolated Syndrome: A Trial to Deliver the Benefits of Vitamin D and Other UVB-Induced Molecules

et al. 2017

View full text Add to dashboard Cite

Low vitamin D and insufficient sun exposure are additive independent risk factors for the development of multiple sclerosis (MS). The usual measure of vitamin D status, serum 25-hydroxy vitamin D [25(OH)D], is also a marker of recent exposure to the UVB rays of sunshine. The main evidence for a protective effect for MS development of higher 25(OH)D comes from observational studies, but this study design cannot separate out whether 25(OH)D is acting as a marker of vitamin D status, sun exposure, or both. In light of a lack of definitive outcomes in MS patients after trials of vitamin D supplementation and the ability of narrowband UVB to induce vitamin D, as well as other immune-regulatory molecules in skin, the Phototherapy for Clinically Isolated Syndrome (PhoCIS) trial was established to investigate the benefits of narrowband UVB, in addition to supplemented vitamin D, on MS development in individuals with Clinically Isolated Syndrome. We propose that the PhoCIS trial provides a fresh approach to re-defining the reported associations of 25(OH)D levels with MS development and progression.

show abstract

“…Furthermore, Disanto et al showed decreased anti-EBNA-1 IgG levels after 12 weeks of vitamin D supplementation in 15 relapsing–remitting MS (RRMS) patients ( p = 0.016) [74]. Another study by Najafipoor et al examined the effect of vitamin D supplementation for 6 months on the anti-VCA IgG and anti-EBNA-1 IgG levels in 40 RRMS patients [75]. They found six patients (15%) with a decline in the level of anti-VCA titers and six patients (15%) with a reduction in anti-EBNA1 titers in the supplemented group.…”

Section: Reviewmentioning

confidence: 99%

Vitamin D deficiency as a risk factor for the development of autoantibodies in patients with ASIA and silicone breast implants: a cohort study and review of the literature

2017

View full text Add to dashboard Cite

The development of autoimmunity and/or autoimmune diseases is multifactorial. Vitamin D is one of the factors that might play a role. We postulated that both the presence of adjuvants and insufficient levels of vitamin D may result in the development of autoimmunity in patients with autoimmune/inflammatory syndrome induced by adjuvants (ASIA) in relation to silicone implant incompatibility. We measured vitamin D levels in 135 patients with ASIA in relation to silicone implant incompatibility and related findings to the presence of autoantibodies that are commonly used to diagnose systemic autoimmune diseases. Furthermore, we systematically reviewed the literature regarding vitamin D deficiency as a risk factor for the development of autoantibodies. Vitamin D measurements were available for analysis in 131 of 135 patients with ASIA in relation to SIIS. Twenty-three patients (18%) tested positive for autoantibodies, from which 18 patients (78%) had either a vitamin D deficiency or insufficiency (median vitamin D level 60.5 mmol/L), whereas five patients (22%) had sufficient vitamin D levels. The risk to develop autoantibodies was significantly increased in vitamin D deficient and/or insufficient patients [RR 3.14; 95% CI, 1.24–7.95; p = 0.009]. Reviewed literature suggested an association between vitamin D levels and the presence and/or titer levels of autoantibodies in different autoimmune diseases. From our current study and from our review of the literature, we conclude that vitamin D deficiency is related to the presence of autoantibodies. Whether vitamin D supplementation results in a decrease of autoimmunity needs to be studied prospectively.

show abstract

The beneficial effects of vitamin D3 on reducing antibody titers against Epstein–Barr virus in multiple sclerosis patients

Cited by 29 publications

References 40 publications

Effect of high-dose vitamin D₃ supplementation on antibody responses against Epstein–Barr virus in relapsing-remitting multiple sclerosis

Effect of high-dose vitamin D₃ supplementation on antibody responses against Epstein–Barr virus in relapsing-remitting multiple sclerosis

Narrowband UVB Phototherapy for Clinically Isolated Syndrome: A Trial to Deliver the Benefits of Vitamin D and Other UVB-Induced Molecules

Vitamin D deficiency as a risk factor for the development of autoantibodies in patients with ASIA and silicone breast implants: a cohort study and review of the literature

Contact Info

Product

Resources

About

The beneficial effects of vitamin D3 on reducing antibody titers against Epstein–Barr virus in multiple sclerosis patients

Cited by 29 publications

References 40 publications

Effect of high-dose vitamin D3 supplementation on antibody responses against Epstein–Barr virus in relapsing-remitting multiple sclerosis

Effect of high-dose vitamin D3 supplementation on antibody responses against Epstein–Barr virus in relapsing-remitting multiple sclerosis

Narrowband UVB Phototherapy for Clinically Isolated Syndrome: A Trial to Deliver the Benefits of Vitamin D and Other UVB-Induced Molecules

Vitamin D deficiency as a risk factor for the development of autoantibodies in patients with ASIA and silicone breast implants: a cohort study and review of the literature

Contact Info

Product

Resources

About

Effect of high-dose vitamin D₃ supplementation on antibody responses against Epstein–Barr virus in relapsing-remitting multiple sclerosis

Effect of high-dose vitamin D₃ supplementation on antibody responses against Epstein–Barr virus in relapsing-remitting multiple sclerosis